De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Oncorus Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Oncorus's earnings have been declining at an average annual rate of -25.8%, while the Biotechs industry saw earnings growing at 17.8% annually.

Belangrijke informatie

-25.8%

Groei van de winst

67.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-290.9%
Nettomarge	n/a
Laatste winstupdate	31 Mar 2023

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Oncorus geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:ONCR Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 23	-91	29	45
31 Dec 22	-77	30	47
30 Sep 22	-76	29	46
30 Jun 22	-73	29	44
31 Mar 22	-70	29	41
31 Dec 21	-65	26	38
30 Sep 21	-57	24	33
30 Jun 21	-62	16	32
31 Mar 21	-59	14	28
31 Dec 20	-57	11	26
30 Sep 20	-57	11	24
30 Jun 20	-43	10	23
31 Mar 20	-38	9	23
31 Dec 19	-35	8	23
31 Dec 18	-18	7	11

Kwaliteitswinsten: ONCR is currently unprofitable.

Groeiende winstmarge: ONCR is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ONCR is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.

Versnelling van de groei: Unable to compare ONCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ONCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).

Rendement op eigen vermogen

Hoge ROE: ONCR has a negative Return on Equity (-290.93%), as it is currently unprofitable.

Oncorus Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus Appoints Scott Canute to Its Board of Directors

Oncorus reports Q3 results

Oncorus, Inc. has filed an IPO in the amount of $86.25 million.

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden